Wockhardt Ltd.
Snapshot View

547.85 -2.00 ▼-0.4%

23 July 2021, 04:00:00 P.M.
Volume: 49,121

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.wockhardt.com
Financial Indicators
Market Cap 6,069.15 Cr.
Earnings per share (EPS) -7.83 Trailing Twelve Months Ending 2021-06
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2021-06
Industry PE 35.17 Trailing Twelve Months Ending 2021-06
Book Value / Share 301.74 Trailing Twelve Months Ending 2021-06
Price to Book Value 1.82 Calculated using Price: 547.85
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 11.08 Cr. 110,781,153 Shares
FaceValue 5
Company Profile

Wockhardt Ltd. is a global pharmaceutical and biotechnology organisation, providing affordable, high-quality medicines for a healthier world. It is India’s leading research-based global healthcare enterprise with relevance in the fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Speciality Hospitals. It is a true Indian Multi-National Company with a multi-ethnic workforce of many Wockhardt Associates from many different nationalities globally. It has many research centres and several manufacturing plants, with businesses ranging from the manufacture and marketing of Pharmaceutical and Bio-pharmaceutical formulations, Active Pharmaceutical Ingredients (APIs) and Vaccines. It is a business in transition. New and innovative business models are in motion to make the most of emerging opportunities. A new drive for growth today permeates every mind-set, process and techno-innovation within Wockhardt.

Business area of the company

The company is a pharmaceutical and biotechnology company. The Company's businesses include manufacture and marketing of pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines.

Awards

2009

  • Outstanding National Citizen Award by National Citizens Guild.
  • Strathmore’s Who’s Who - Social Entrepreneur of the Year.

2010

  • AmeriCares India Spirit of Humanity Award.
  • USA BF Foundation of the Year Award.
  • HEF Award for ‘Outstanding contribution to the teaching community with special reference to Human Values.
  • Best Pharma CSR award at the Pharmaceutical Leadership Summit.

2011

  • IDF - CSR Award.

2012

  • Inclusive India Award under the Corporate category for ‘Best Social Work in the Realm of Primary Healthcare’.
  • IPE CSR Corporate Governance Award.

2013

  • Rajiv Gandhi Global Excellence Award.
  • Rajiv Gandhi Excellence Award.
  • Bharat Gaurav Award.
  • Asian CSR Leadership Awards.
  • CSR Excellence & Leadership Award.
  • Asia Peace Award.

2015

  • Best CSR Project in Healthcare for Mobile 1000 Medical vans - India CSR.
  • Best Community Development Award for Mobile 1000 - World CSR Congress.
  • CSR Professional of the Year - World CSR Congress.
  • Maharashtra Class Owners Association Meritorious Award for valuable contribution in the field of education.
  • Bronze Award for Table Calendar - A.B.C.I (Association of Business Communicators of India).
  • Social Entrepreneur of the Year 2015 - Pharma Leaders.
  • Swachh Bharat Samman - India CSR.
  • Best Environment Friendly Project for Bio-Toilets - Asian CSR Leadership Awards.

2016

  • CSR Leadership Award.
  • Lions CSR Precious Award.
  • Champion of WSIS Prize 2016 - World Summit on the Information Society.
  • Outstanding Leadership Award - Nurturing the Future Foundation.
  • Peace Leader of the Year 2016 - 7th India Leadership Conclave and Indian Affairs Business Leadership Awards 2016.
  • Best Service Award for Significant National Contribution - Institute of Technology & Science.
  • Asia Healthcare Excellence Award - CMO Asia.

2017

  • Excellence Award for Corporate Social Responsibility & Peace Mission - Indian Virtual University for Peace and Education (IVUP).
  • Global NGO Excellence Award for Excellence in Mother & Child Care - World CSR Day.
  • CSR Humanity Award’ by India CSR.
  • Lifetime Achievement Award from the National Institute of Cleanliness Education and Research (NICER).
  • Indian of the Year 2017 (Social Service) by ILC Power Brand.
  • The Rotary Peace Ambassador Award by Rotary.
  • CSR Impact Award by IndiaCSR.
  • Magnificient Man Choice Award with specialization in CEO CSR Excellence from Hopewill International Business Academy.

2018

  • Game Changer Award by The HR Club.
  • Sabarmati Festival Foundation Award for Outstanding Social Work from Sabarmati Festival Foundation.
  • Divyang Ratna Award 2018 by Disable Welfare Trust of India.

2019

  • Mumbai Heroes Award from Blossom Media Pvt Ltd at the Humanity First Conclave.
  • Inspiring Indian Award from Indian Ex Defence Service Employees Chamber of Commerce & Industries (IESECCI).
  • Award for Peace Mobilization from Poddar Foundation at the Insure your Mental Health Conference (Celebrating World Health Day).
  • Inspirational Indian of the Year at the The Mumbai Achievers Awards 2019 by Mumbai Halchal.
  • Bharat Shree Award 2019.
  • Rotary Award from Rotary Club of Mumbai Khar.
  • H F F Excellence Award from Humanity First Foundation.

2020

  • ‘For the Sake of Honour’ Award from Rotary.
  • Excellence in Human Welfare Award from Charity with a Twist, Nargis Dutt Foundation, ECOMO.

Milestones

2010

  • Wockhardt receives US FDA approval for antibacterial Levofloxacin.
  • Wockhardt launches Prostate drug Flomax in the United States on Day-1.
  • Wockhardt receives US FDA approval for the generic version of Toprol XL, a cardiac drug.

2011

  • Wockhardt launches generic version of Protonix tablets in the US.
  • Wockhardt receives US FDA approval for generic version of Effexor XR capsules.
  • Wockhardt launches three new products in three weeks, in the United States.
  • Wockhardt receives tentative US FDA approval for generic version of Patanol ophthalmic solution.

2012

  • Wockhardt launches generic version of anti-­ulcer drug Prevacid.
  • Wockhardt receives US FDA approval for generic version of Parkinsonism drug Requip XL.
  • Wockhardt receives tentative US FDA approval for generic version of anti-psychotic drug Geodon.
  • Wockhardt receives US FDA approval for generic version of Parkinson’s drug Comtan.

2013

  • Wockhardt receives the 'Best Enterprise' award from the Europe Business Assembly.
  • Wockhardt launches generic version of anti-convulsant drug Lamictal XR.

2014

  • Wockhardt’s drug discovery gets a boost with fast track approval by USFDA.

2015

  • Wockhardt Receives ANDA Approval for pain medication Oxycodone liquid.
  • Wockhardt receives Qualified Infectious Disease Product (QIDP) designation for its new Drug WCK 4873 from U.S. FDA -US FDA grants breakthrough (QIDP) drug discovery status to the New Antibiotic of Wockhardt.

2018

  • Wockhardt sets up its first manufacturing and R&D unit in Middle East.

2019

  • Wockhardt has received approval from the United States Food & Drug Administration (US FDA) for an ANDA for 50mg injection of Decitabine, which is used to treat certain forms of cancer.
  • Wockhardt has received approval from the United States Food & Drug Administration (US FDA) for an ANDA for 100mg and 400mg tablets of Imatinib Mesylate, which is used to treat many kinds of cancers and tumors.

2020

  • Wockhardt has entered into an agreement with the UK Government to fill finish COVID-19 vaccines.
  • Wockhardt has received approval from Indian drug regulator -- Drug Controller General of India (DCGI) for 2 new antibiotics, EMROK (IV) and EMROK O (Oral), which is used to treat acute bacterial skin and skin structure Infections including diabetic foot infections and concurrent bacteraemia based on the Phase 3 study involving 500 patients in 40 centres across India.
  • Wockhardt has received approval for the transfer of business comprising 62 products and line extensions along with related business assets and liabilities, contracts, permits, intellectual properties, employees, marketing, sales and distribution of the same in the Domestic Branded Division in India, Nepal, Bhutan, Sri Lanka and Maldives; and manufacturing facility in Baddi, Himachal Pradesh, India, where some of the said pharmaceutical products which are being transferred are manufactured and together referred to as the Business Undertaking by way of a slump sale to Dr. Reddy's Laboratories for Rs 1,850 crore as per the terms and conditions specified in the Business Transfer Agreement (BTA).
  • Wockhardt announced COVID-19 vaccine partnership with UK Government.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-0.36%
1 Week
-4.28%
1 Month
-2.43%
3 Month
+8.78%
6 Month
+6.70%
1 Year
+100.46%
2 Year
+64.74%
5 Year
-43.82%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 102.78 30.04 12.49 7.07 -6.42 -21.81 -7.94 -1.64 22.99
Return on Capital Employed (%) 43.10 18.98 11.25 6.87 -0.31 -5.47 -0.56 1.32 20.10
Return on Assets (%) 25.78 13.36 5.84 3.25 -2.69 -7.93 -2.79 -0.57 9.11

Balance Sheet View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Shh. Funds 2,704 3,581 3,715 3,775 3,337 2,852 2,675 2,672 3,377
Non Curr. Liab. 1,521 1,161 1,872 1,893 3,151 2,089 1,703 1,195 497
Curr. Liab. 1,773 1,743 1,773 1,842 1,979 2,692 2,864 3,497 3,118
Minority Int. 136 144 465 382 346 330 386 383
Equity & Liab. 5,998 6,622 7,505 7,976 8,849 7,978 7,571 7,749 7,375
Non Curr. Assets 2,672 3,266 3,983 4,024 4,314 4,599 4,756 5,320 4,951
Curr. Assets 3,327 3,356 3,522 3,952 4,535 3,380 2,815 2,430 2,424
Misc. Exp. not W/O
Total Assets 5,998 6,622 7,505 7,976 8,849 7,978 7,571 7,749 7,375

Profit Loss View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Net Sales 5,609 4,830 4,482 4,453 4,015 3,937 4,158 3,325 2,762
Other Income 54 38 67 66 101 120 21 60 130
Total Income 5,663 4,869 4,548 4,519 4,115 4,057 4,179 3,385 2,892
Total Expenditure -3,550 -3,805 -3,772 -3,959 -3,988 -3,935 -4,051 -3,082 -2,809
PBIDT 2,114 1,064 776 560 127 122 129 303 83
Interest -215 -83 -55 -129 -225 -255 -265 -276 -249
Depreciation -122 -140 -145 -142 -149 -150 -164 -224 -246
Taxation -258 -48 -163 -38 21 -26 84 153 -227
Exceptional Items 62 50 -358 1,328
PAT 1,579 843 413 252 -226 -667 -217 -43 689

Cash Flow View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 1,532 1,476 355 72 -269 68 183 649 -287
Cash Fr. Inv. 1,085 -852 -207 -818 -687 630 95 -156 1,470
Cash Fr. Finan. -2,246 -601 -76 254 1,254 -769 -776 -680 -1,171
Net Change 372 23 73 -492 298 -71 -499 -186 12
Cash & Cash Eqvt 1,050 1,102 1,159 665 964 897 397 219 232

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 74.06 74.04 72.40 72.13 72.13 72.12 72.12 72.12 69.68
Public 25.94 25.96 27.60 27.87 27.87 27.88 27.88 27.88 30.32
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 2.07 3.96 24.70 37.12 26.42 22.41 10.14 18.71 34.44

Announcements View Details

Fri, 23 Jul 2021
Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011.
The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011 on July 22 2021 for Humuza Consultants
Fri, 23 Jul 2021
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on July 22 2021 for Themisto Trustee Company Pvt Ltd
Thu, 22 Jul 2021
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release in respect of the Financial Results for the quarter ended 30th June 2021.

Technical Scans View Details

Fri, 23 Jul 2021
Stock Underperforming Benchmark Index in both 1 Week and 3 Month Stock Underperforming Benchmark Index in both 1 Week and 3 Month
Stock Underperforming Sectoral Index in both 1 Week and 3 Month Stock Underperforming Sectoral Index in both 1 Week and 3 Month
Decreasing Relative Strength - Benchmark index Decreasing Relative Strength - Benchmark index
Closing Near 100 EMA Closing Near 100 EMA
Close Crossing 100 EMA From Above Close Crossing 100 EMA From Above

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 166,513.85 694.00 +1.0%
Divi's Laboratories Ltd. 128,088.59 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. 90,175.51 5,420.50 +0.7%
Cipla Ltd. 76,510.04 948.50 -0.1%
Cadila Healthcare Ltd. 62,965.29 615.05 -0.9%
Aurobindo Pharma Ltd. 56,484.48 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. 56,291.69 3,915.00 -1.8%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 57.34 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 64.55 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.21 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 31.81 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 29.51 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.59 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 374.38 3,915.00 -1.8%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.58 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 13.78 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.15 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 4.17 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 4.85 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.58 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.25 3,915.00 -1.8%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 0.18 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 10.09 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 12.53 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 3,915.00 -1.8%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 17,131.99 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 3,915.00 -1.8%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 1,546.98 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 3,915.00 -1.8%